Adcendo has struck a Keytruda supply agreement with MSD, positioning the Danish biotech to study an antibody-drug conjugate (ADC) with the blockbuster checkpoint inhibitor.
Tag Archive for: combination therapy
BioNTech SEA study recently published in Nature on the use of mRNA “vaccines” targeting cancer neoantigens in triple-negative breast cancer (TNBC) has generated considerable attention in scientific circles. However, with only 14 patients treated in this Phase I trial, it is far too early to declare a breakthrough. Still, the highly encouraging data breathe new life into a cancer vaccine approach that in recent years had fallen behind antibodies, ADCs and checkpoint inhibitors.